A Toll-Like Receptor-2-Directed Fusion Protein Vaccine against Tuberculosis | Zendy

Bin Wang | Zendy; Marcela HenaoTamayo | Zendy; M. Harton | Zendy; Diane Ordway | Zendy; Crystal A. Shanley | Zendy; Randall J. Basaraba | Zendy; Ian M. Orme | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Toll-Like Receptor-2-Directed Fusion Protein Vaccine against Tuberculosis

Author(s) -

Bin Wang,

Marcela HenaoTamayo,

M. Harton,

Diane Ordway,

Crystal A. Shanley,

Randall J. Basaraba,

Ian M. Orme

Publication year - 2007

Publication title -

clinical and vaccine immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.649

H-Index - 77

eISSN - 1556-6811

pISSN - 1556-679X

DOI - 10.1128/cvi.00077-07

Subject(s) - fusion protein , mycobacterium tuberculosis , restriction site , biology , virology , primer (cosmetics) , fusion gene , microbiology and biotechnology , recombinant dna , gene , tuberculosis , chemistry , restriction enzyme , genetics , medicine , pathology , organic chemistry

A fusion protein designated CSU-F36 was constructed that consisted of acylated Rv1411, a potent Toll-like receptor-2 agonist, fused to ESAT-6, a well-characterized immunogenic protein from Mycobacterium tuberculosis. The CSU-F36 fusion protein strongly induced interleukin 12 secretion from macrophages and induced the increased accumulation of CD4 T cells capable of secreting gamma interferon in the lungs of infected mice. These mice were significantly protected from low-dose aerosol challenge with M. tuberculosis, even with CSU-F36 delivered in a simple depot material. This "natural adjuvant"-containing system could potentially bypass the need for more expensive TH1-inducing adjuvants and could be applied to many mycobacterial proteins to provide effective and cheap new vaccines against tuberculosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research